A promising photobiomodulation study appears in a well-regarded journal. Within days, marketing copy across the category starts implying the finding applies to products that share almost nothing with the device in the study. A published study is not permission to make a claim — it’s a description of what happened under specific conditions, with specific parameters, in a specific population. This guide covers how to read one properly, and where the line sits between citing research and overclaiming.
RedVance manufactures red light therapy panels. This guide covers evidence literacy for brands referencing research; what may actually be claimed about any device in any market is a question for a qualified regulatory professional in that market.
Read the parameters before the conclusion
The single most common error in citing PBM research is reading the abstract’s conclusion and stopping there. In this field, the parameters are the study. Two interventions using red light can be entirely different interventions if they differ on:
| Parameter | Why it determines applicability |
|---|---|
| Wavelength | Different wavelengths behave differently; a finding at one does not transfer to another |
| Irradiance | The delivery rate, which combined with time determines dose |
| Dose (J/cm²) | The total energy delivered — the parameter most often omitted in marketing references |
| Session duration and frequency | A protocol, not a one-off exposure |
| Delivery method and distance | Contact, near-field or at distance changes what actually reaches tissue |
| Target area and depth | Surface versus deeper tissue are different problems |
What study design establishes, and what it doesn’t
| Design | What it can establish |
|---|---|
| In vitro / cell study | A mechanism may exist; says nothing about clinical outcomes in people |
| Animal study | An effect in that animal model; translation to humans is not automatic |
| Case report / series | Something was observed; no control, no generalisability |
| Open-label human study | Observation without blinding — vulnerable to expectation effects |
| Randomised controlled trial | The strongest single-study design; strength still depends on size and rigour |
| Systematic review / meta-analysis | Synthesises multiple studies; quality depends entirely on the studies included |
A well-conducted randomised controlled trial is meaningfully stronger evidence than a case series. But design and size are separate questions, which is where the next section comes in.
Sample size: how research questions open, not close
A rigorous double-blind randomised trial with a few dozen participants can be a legitimate and genuinely interesting scientific contribution. It is also, usually, too small to settle a question — small trials are how research questions get opened, and replication at larger scale is how they get closer to settled.
Treating an early-stage finding as established is one of the most common ways evidence gets overstated commercially in this category. The study itself may be entirely sound; the problem is the leap from “this warrants further investigation” to “our product does this.”
Journal quality is not claim substantiation
Publication in a well-regarded, peer-reviewed journal indicates the study met that journal’s standards for methodological quality and novelty. That’s meaningful, and it’s worth distinguishing from predatory or non-reviewed publication.
But it answers a different question from the one a brand needs answered. Journal quality speaks to whether the research was conducted and reported properly. It says nothing about whether the finding is large enough, replicated enough, or applicable enough to your specific product to support a marketing claim — which is a separate evidentiary and regulatory question entirely.
Scientific signal versus commercial claim
| Scientific signal | Commercial claim |
|---|---|
| “This finding warrants further investigation” | “This product does X” |
| Holds within stated parameters and population | Asserted to a buyer about their situation |
| Provisional, subject to replication | Treated as reliable by the person reading it |
| Judged by the research community | Judged by advertising regulators and, in some cases, device regulators |
The gap between the columns is where most overclaiming in this category originates — usually not through deliberate deception, but through a brand genuinely excited about real research and not registering that the leap across that gap is a regulated act. Which claims are permissible varies by market and is mapped in our market-by-market compliance hub, with the general claims discipline in our claims verification guide.
Referencing research responsibly
- Describe research as research, not as a product attribute. “Research in this area is investigating X” is a different statement from “our device does X.”
- State the parameters and context where you reference a study, rather than citing a conclusion in isolation.
- Don’t imply transfer. A study on a different device, at different parameters, does not describe your product, and implying otherwise is the specific move that creates exposure.
- Get outcome language reviewed per market before publication — this is the step that catches problems while they’re still cheap to fix.
The distinction between operational guidance (safe) and outcome claims (regulated) is laid out in detail in our customer education guide — the same line applies to research references.
What your own device documentation does establish
Worth ending on, because it’s the constructive alternative. Published research about photobiomodulation generally is not evidence about your specific product. What is evidence about your specific product is its own performance documentation — measured irradiance, verified spectrum, uniformity, thermal behaviour — covered in our evidence package hub.
That documentation supports precise, defensible statements about what the device physically delivers. It doesn’t support outcome claims either — but it’s yours, it’s verifiable, and competitors citing the same general research have nothing comparable.
The evidence literacy checklist
- Parameters checked first — wavelength, irradiance, dose, duration, frequency, delivery method.
- Parameters compared against your actual device; differences noted honestly.
- Study design identified and its limits understood.
- Sample size noted, and early-stage findings treated as provisional.
- Journal quality assessed, but not treated as claim substantiation.
- Any reference framed as research, not as a product attribute.
- All outcome-related language reviewed per market before publication.
- Own device documentation used as the basis for device-specific statements.
Terms used here are defined in our glossary, and the full library is on our blog index.
What a manufacturer can usefully contribute: accurate device performance documentation so a brand’s device-specific statements rest on measured data rather than borrowed research, and clarity about what that documentation does and does not establish. Supplying a brand with research citations as though they were product evidence is the opposite of useful — it hands over exposure dressed as support.
Frequently asked questions
Does a published study allow me to make a marketing claim about my device?
Generally not by itself. A study establishes what was observed under its specific conditions with its specific device and parameters. A marketing claim about a different device, with different parameters, sold for general wellness use is a separate assertion requiring its own substantiation, and in many markets, its own regulatory position. Citing research does not transfer its findings to an unrelated product.
What should I check first when reading a photobiomodulation study?
The parameters before the conclusion: wavelength, irradiance, dose, treatment duration, frequency, and the distance or delivery method used. If those differ from the device you sell, the study describes a different intervention regardless of how similar the technology sounds. Parameters are what make a PBM study applicable or inapplicable to a given product.
How much does sample size matter in evaluating a study?
Substantially. A well-designed randomised controlled trial with a small sample can be a legitimate and valuable scientific signal while still being too small to support confident general claims. Small studies are how research questions get opened, not how they get settled — and treating an early-stage finding as established is one of the most common ways evidence gets overstated commercially.
What is the difference between a scientific signal and a commercial claim?
A scientific signal is a finding worth investigating further — interesting, possibly important, not yet settled. A commercial claim is an assertion made to a buyer that the product will do something. The gap between them is usually replication, sample size and regulatory position, and treating the first as licence for the second is where most overclaiming in this category originates.
Does journal reputation determine whether a finding can be used commercially?
No. A reputable journal indicates the study met peer review standards for publication, which is meaningful, but it says nothing about whether the finding is large enough, replicated enough, or applicable enough to a specific commercial product to support a marketing claim. Journal quality and claim substantiation are different questions.
How should a brand reference research responsibly?
Describe research as research rather than as a product claim, state the parameters and context, avoid implying that findings from a different device or configuration apply to your product, and have all outcome-related language reviewed against the advertising and regulatory requirements of each market you sell in before publication.
Build statements on your own data
Tell us the model you’re working with and we’ll share what performance documentation exists for it — measured figures you can make precise statements about, rather than research findings that describe someone else’s device.
Request device documentation →
EN